Verona Pharma plc

DB:I9SA Stock Report

Market Cap: €5.8b

Verona Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:I9SA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 May 25Sell€3,090,147Mark HahnIndividual387,008€8.02
02 May 25Sell€386,253David ZaccardelliIndividual48,376€8.02
12 Mar 25Sell€75,792Kathleen RickardIndividual9,908€7.65
06 Dec 24Sell€4,178,342Mark HahnIndividual110,245€37.92
06 Dec 24Sell€4,124,721David ZaccardelliIndividual108,834€37.92
02 Dec 24Sell€597,691David ZaccardelliIndividual15,666€38.16
02 Dec 24Sell€540,125Mark HahnIndividual14,155€38.16
26 Nov 24Sell€11,460Mark HahnIndividual300€38.20
25 Nov 24Sell€1,122,130Kathleen RickardIndividual30,000€37.40
25 Nov 24Sell€7,631David ZaccardelliIndividual200€38.16
18 Nov 24Buy€31,505David EbsworthIndividual2,500€12.60
11 Nov 24Sell€11,267Mark HahnIndividual300€37.56
11 Nov 24Sell€11,267David ZaccardelliIndividual300€37.56
06 Nov 24Buy€184,856Christina AckermannIndividual5,235€35.31
06 Nov 24Buy€175,999David EbsworthIndividual4,920€35.77
04 Nov 24Sell€522,063Mark HahnIndividual16,209€32.24
04 Nov 24Sell€568,237David ZaccardelliIndividual17,629€32.27
25 Oct 24Sell€585,720David ZaccardelliIndividual18,102€32.36
25 Oct 24Sell€584,671Mark HahnIndividual18,070€32.36
22 Oct 24Sell€2,130,529Mark HahnIndividual525,768€4.06
22 Oct 24Sell€2,083,793David ZaccardelliIndividual514,152€4.06
11 Sep 24Sell€2,047,155Mark HahnIndividual600,000€3.41
11 Sep 24Sell€2,047,373David ZaccardelliIndividual600,000€3.41
13 Aug 24Sell€1,164,441Mark HahnIndividual49,800€23.74
12 Aug 24Buy€94,486David EbsworthIndividual4,500€21.00
12 Aug 24Sell€4,580Mark HahnIndividual200€22.90
12 Aug 24Sell€4,580David ZaccardelliIndividual200€22.90

Insider Trading Volume

Insider Buying: I9SA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of I9SA?
Owner TypeNumber of SharesOwnership Percentage
State or Government63,5000.0697%
General Public502,9880.552%
Individual Insiders4,136,5934.54%
VC/PE Firms18,585,56420.4%
Institutions67,854,46974.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 72.16% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.2%
RA Capital Management, L.P.
12,022,224€769.3m54.6%12.92%
7.2%
Perceptive Advisors LLC
6,563,340€420.0m2.68%18.12%
6.05%
Janus Henderson Group plc
5,516,889€353.0m231%0.17%
4.3%
Darwin Global Management Limited
3,923,204€251.0m384%22.04%
3.79%
Frazier Life Sciences Management, LP
3,457,850€221.3m2.18%11.76%
3.17%
Eventide Asset Management, LLC
2,893,437€185.1m-7.62%3.89%
3.13%
RTW Investments, LP
2,848,800€182.3m56.4%3.18%
2.95%
New Enterprise Associates, Inc.
2,688,565€172.0m-51.9%12.56%
2.55%
Summit Partners Public Asset Management, LLC
2,323,115€148.7m22.1%7.27%
2.34%
Wellington Management Group LLP
2,131,502€136.4m-29.5%0.03%
2.05%
T. Rowe Price Group, Inc.
1,866,280€119.4m1.79%0.01%
1.96%
Maverick Capital, Ltd.
1,783,498€114.1m-43%2.21%
1.92%
David Zaccardelli
1,748,771€111.9m21.5%no data
1.79%
Adage Capital Management, L.P.
1,631,000€104.4m382%0.22%
1.76%
Morgan Stanley, Investment Banking and Brokerage Investments
1,607,410€102.9m10.8%0.01%
1.68%
Hood River Capital Management LLC
1,532,348€98.1m3.17%1.81%
1.58%
Vivo Capital, LLC
1,438,785€92.1m-37%8.71%
1.58%
Caligan Partners, LP
1,436,878€91.9m0%20.54%
1.5%
Holocene Advisors, LP
1,366,680€87.5m0%0.29%
1.46%
Mark Hahn
1,328,624€85.0m0.26%no data
1.39%
Federated Hermes, Inc.
1,267,761€81.1m-30.5%0.21%
1.38%
Jennison Associates LLC
1,261,153€80.7m-33.3%0.06%
1.19%
Farallon Capital Management, L.L.C.
1,084,989€69.4m0%0.49%
1.14%
Goldman Sachs Group, Investment Banking and Securities Investments
1,034,621€66.2m280%0.03%
1.11%
Putnam LLC
1,012,125€64.8m27.9%0.06%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 11:44
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Verona Pharma plc is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioBerenberg
Thomas ShraderBTIG
Edward NashCanaccord Genuity